Login Register Cart 0
Review Article

靶向NAD+生物合成酶的小分子调节酶

卷 29, 期 10, 2022

发表于: 25 August, 2021

页: [1718 - 1738] 页: 21

弟呕挨: 10.2174/0929867328666210531144629

价格: $65

摘要

烟酰胺腺嘌呤二核苷酸(NAD+)作为电子的活化载体，在许多代谢途径中起着关键作用。除了作为氧化还原反应的辅助因子外，NAD+还作为各种酶转化的底物，如腺苷化和adp-核糖基化。维持细胞NAD+稳态已被认为是一种有效的抗衰老策略。鉴于NAD+在调节广泛的细胞事件中的重要性，靶向NAD+代谢的小分子已被寻求作为治疗线粒体疾病和年龄相关疾病的治疗干预措施。本文将综述NAD+生物合成酶的小分子调节因子。重点将关注这些分子的发现和发展、作用机制及其治疗潜力。

关键词: 烟酰胺腺嘌呤二核苷酸(NAD+)，代谢途径，电子，氧化还原反应，酶的转化，治疗潜力。

« Previous Next »
[1]
Michan, S.; Sinclair, D. Sirtuins in mammals: insights into their biological function. Biochem. J., 2007, 404(1), 1-13.
[http://dx.doi.org/10.1042/BJ20070140] [PMID: 17447894 ]
[2]
D’Amours, D.; Desnoyers, S.; D’Silva, I.; Poirier, G.G. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem. J., 1999, 342(Pt 2), 249-268.
[http://dx.doi.org/10.1042/bj3420249] [PMID: 10455009 ]
[3]
Schreiber, V.; Dantzer, F.; Ame, J.C.; de Murcia, G. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol., 2006, 7(7), 517-528.
[http://dx.doi.org/10.1038/nrm1963] [PMID: 16829982 ]
[4]
Lee, H.C. Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. Annu. Rev. Pharmacol. Toxicol., 2001, 41, 317-345.
[http://dx.doi.org/10.1146/annurev.pharmtox.41.1.317] [PMID: 11264460 ]
[5]
Lombard, D.B.; Chua, K.F.; Mostoslavsky, R.; Franco, S.; Gostissa, M.; Alt, F.W. DNA repair, genome stability, and aging. Cell, 2005, 120(4), 497-512.
[http://dx.doi.org/10.1016/j.cell.2005.01.028] [PMID: 15734682 ]
[6]
Blander, G.; Guarente, L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem., 2004, 73, 417-435.
[http://dx.doi.org/10.1146/annurev.biochem.73.011303.073651] [PMID: 15189148 ]
[7]
Hassa, P.O.; Haenni, S.S.; Elser, M.; Hottiger, M.O. Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going? Microbiol. Mol. Biol. Rev., 2006, 70(3), 789-829.
[http://dx.doi.org/10.1128/MMBR.00040-05] [PMID: 16959969 ]
[8]
Herceg, Z.; Wang, Z.Q. Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat. Res., 2001, 477(1-2), 97-110.
[http://dx.doi.org/10.1016/S0027-5107(01)00111-7] [PMID: 11376691 ]
[9]
Kharechkina, E.S.; Nikiforova, A.B.; Teplova, V.V.; Odinokova, I.V.; Krestinina, O.V.; Baburina, Y.L.; Kruglova, S.A.; Kruglov, A.G. Regulation of permeability transition pore opening in mitochondria by external NAD(H). Biochim. Biophys. Acta, Gen. Subj., 2019, 1863(5), 771-783.
[http://dx.doi.org/10.1016/j.bbagen.2019.01.003] [PMID: 30763605 ]
[10]
Rasola, A.; Bernardi, P. The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis. Apoptosis, 2007, 12(5), 815-833.
[http://dx.doi.org/10.1007/s10495-007-0723-y] [PMID: 17294078 ]
[11]
Kwong, J.Q.; Molkentin, J.D. Physiological and pathological roles of the mitochondrial permeability transition pore in the heart. Cell Metab., 2015, 21(2), 206-214.
[http://dx.doi.org/10.1016/j.cmet.2014.12.001] [PMID: 25651175 ]
[12]
Hunter, D.R.; Haworth, R.A. The Ca2+-induced membrane transition in mitochondria. I. The protective mechanisms. Arch. Biochem. Biophys., 1979, 195(2), 453-459.
[http://dx.doi.org/10.1016/0003-9861(79)90371-0] [PMID: 383019 ]
[13]
Haworth, R.A.; Hunter, D.R. Allosteric inhibition of the Ca2+-activated hydrophilic channel of the mitochondrial inner membrane by nucleotides. J. Membr. Biol., 1980, 54(3), 231-236.
[http://dx.doi.org/10.1007/BF01870239] [PMID: 6248646 ]
[14]
Kurnasov, O.; Goral, V.; Colabroy, K.; Gerdes, S.; Anantha, S.; Osterman, A.; Begley, T.P. NAD biosynthesis: identification of the tryptophan to quinolinate pathway in bacteria. Chem. Biol., 2003, 10(12), 1195-1204.
[http://dx.doi.org/10.1016/j.chembiol.2003.11.011] [PMID: 14700627 ]
[15]
Belenky, P.; Bogan, K.L.; Brenner, C. NAD+ metabolism in health and disease. Trends Biochem. Sci., 2007, 32(1), 12-19.
[http://dx.doi.org/10.1016/j.tibs.2006.11.006] [PMID: 17161604 ]
[16]
Tempel, W.; Rabeh, W.M.; Bogan, K.L.; Belenky, P.; Wojcik, M.; Seidle, H.F.; Nedyalkova, L.; Yang, T.; Sauve, A.A.; Park, H.W.; Brenner, C. Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol., 2007, 5(10), e263.
[http://dx.doi.org/10.1371/journal.pbio.0050263] [PMID: 17914902 ]
[17]
Schutz, G.; Feigelson, P. Purification and properties of rat liver tryptophan oxygenase. J. Biol. Chem., 1972, 247(17), 5327-5332.
[http://dx.doi.org/10.1016/S0021-9258(20)81108-9] [PMID: 4626718 ]
[18]
Shimizu, T.; Nomiyama, S.; Hirata, F.; Hayaishi, O. Indoleamine 2,3-dioxygenase. Purification and some properties. J. Biol. Chem., 1978, 253(13), 4700-4706.
[http://dx.doi.org/10.1016/S0021-9258(17)30447-7] [PMID: 26687]
[19]
Magni, G.; Amici, A.; Emanuelli, M.; Raffaelli, N.; Ruggieri, S. Enzymology of NAD+ synthesis. Adv. Enzymol. Relat. Areas Mol. Biol., 1999, 73, 135-182, xi. [xi.].
[PMID: 10218108]
[20]
Nishizuka, Y.; Hayaishi, O. Enzymic synthesis of niacin nucleotides from 3-hydroxyanthranilic acid in mammalian liver. J. Biol. Chem., 1963, 238, 483-485.
[http://dx.doi.org/10.1016/S0021-9258(19)84026-7] [PMID: 13938817]
[21]
Preiss, J.; Handler, P. Biosynthesis of diphosphopyridine nucleotide. I. Identification of intermediates. J. Biol. Chem., 1958, 233(2), 488-492.
[http://dx.doi.org/10.1016/S0021-9258(18)64789-1] [PMID: 13563526 ]
[22]
Belenky, P.; Racette, F.G.; Bogan, K.L.; McClure, J.M.; Smith, J.S.; Brenner, C. Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+. Cell, 2007, 129(3), 473-484.
[http://dx.doi.org/10.1016/j.cell.2007.03.024] [PMID: 17482543 ]
[23]
Fletcher, R.S.; Ratajczak, J.; Doig, C.L.; Oakey, L.A.; Callingham, R.; Da Silva Xavier, G.; Garten, A.; Elhassan, Y.S.; Redpath, P.; Migaud, M.E.; Philp, A.; Brenner, C.; Canto, C.; Lavery, G.G. Nicotinamide riboside kinases display redundancy in mediating nicotinamide mononucleotide and nicotinamide riboside metabolism in skeletal muscle cells. Mol. Metab., 2017, 6(8), 819-832.
[http://dx.doi.org/10.1016/j.molmet.2017.05.011] [PMID: 28752046 ]
[24]
Tran, A.; Yokose, R.; Cen, Y. Chemo-enzymatic synthesis of isotopically labeled nicotinamide riboside. Org. Biomol. Chem., 2018, 16(19), 3662-3671.
[http://dx.doi.org/10.1039/C8OB00552D] [PMID: 29714801 ]
[25]
Ratajczak, J.; Joffraud, M.; Trammell, S.A.; Ras, R.; Canela, N.; Boutant, M.; Kulkarni, S.S.; Rodrigues, M.; Redpath, P.; Migaud, M.E.; Auwerx, J.; Yanes, O.; Brenner, C.; Cantó, C. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nat. Commun., 2016, 7, 13103.
[http://dx.doi.org/10.1038/ncomms13103] [PMID: 27725675 ]
[26]
Trammell, S.A.; Schmidt, M.S.; Weidemann, B.J.; Redpath, P.; Jaksch, F.; Dellinger, R.W.; Li, Z.; Abel, E.D.; Migaud, M.E.; Brenner, C. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat. Commun., 2016, 7, 12948.
[http://dx.doi.org/10.1038/ncomms12948] [PMID: 27721479 ]
[27]
Ryu, D.; Zhang, H.; Ropelle, E.R.; Sorrentino, V.; Mázala, D.A.; Mouchiroud, L.; Marshall, P.L.; Campbell, M.D.; Ali, A.S.; Knowels, G.M.; Bellemin, S.; Iyer, S.R.; Wang, X.; Gariani, K.; Sauve, A.A.; Cantó, C.; Conley, K.E.; Walter, L.; Lovering, R.M.; Chin, E.R.; Jasmin, B.J.; Marcinek, D.J.; Menzies, K.J.; Auwerx, J. NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation. Sci. Transl. Med., 2016, 8(361), 361ra139.
[http://dx.doi.org/10.1126/scitranslmed.aaf5504] [PMID: 27798264 ]
[28]
Vaur, P.; Brugg, B.; Mericskay, M.; Li, Z.; Schmidt, M.S.; Vivien, D.; Orset, C.; Jacotot, E.; Brenner, C.; Duplus, E. Nicotinamide riboside, a form of vitamin B3, protects against excitotoxicity-induced axonal degeneration. FASEB J., 2017, 31(12), 5440-5452.
[http://dx.doi.org/10.1096/fj.201700221RR] [PMID: 28842432 ]
[29]
Wu, L.E.; Sinclair, D.A. Restoring stem cells - all you need is NAD. Cell Res., 2016, 26(9), 971-972.
[http://dx.doi.org/10.1038/cr.2016.80] [PMID: 27339086 ]
[30]
Camacho-Pereira, J.; Tarragó, M.G.; Chini, C.C.S.; Nin, V.; Escande, C.; Warner, G.M.; Puranik, A.S.; Schoon, R.A.; Reid, J.M.; Galina, A.; Chini, E.N. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab., 2016, 23(6), 1127-1139.
[http://dx.doi.org/10.1016/j.cmet.2016.05.006] [PMID: 27304511 ]
[31]
Covarrubias, A.J.; Kale, A.; Perrone, R.; Lopez-Dominguez, J.A.; Pisco, A.O.; Kasler, H.G.; Schmidt, M.S.; Heckenbach, I.; Kwok, R.; Wiley, C.D.; Wong, H.S.; Gibbs, E.; Iyer, S.S.; Basisty, N.; Wu, Q.; Kim, I.J.; Silva, E.; Vitangcol, K.; Shin, K.O.; Lee, Y.M.; Riley, R.; Ben-Sahra, I.; Ott, M.; Schilling, B.; Scheibye-Knudsen, M.; Ishihara, K.; Quake, S.R.; Newman, J.; Brenner, C.; Campisi, J.; Verdin, E. Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. Nat Metab, 2020, 2(11), 1265-1283.
[http://dx.doi.org/10.1038/s42255-020-00305-3] [PMID: 33199924 ]
[32]
Massudi, H.; Grant, R.; Braidy, N.; Guest, J.; Farnsworth, B.; Guillemin, G.J. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One, 2012, 7(7), e42357.
[http://dx.doi.org/10.1371/journal.pone.0042357] [PMID: 22848760 ]
[33]
Cantó, C.; Auwerx, J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol. Metab., 2009, 20(7), 325-331.
[http://dx.doi.org/10.1016/j.tem.2009.03.008] [PMID: 19713122 ]
[34]
Cantó, C.; Jiang, L.Q.; Deshmukh, A.S.; Mataki, C.; Coste, A.; Lagouge, M.; Zierath, J.R.; Auwerx, J. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab., 2010, 11(3), 213-219.
[http://dx.doi.org/10.1016/j.cmet.2010.02.006] [PMID: 20197054 ]
[35]
Cantó, C.; Auwerx, J. Targeting sirtuin 1 to improve metabolism: all you need is NAD.(+)? Pharmacol. Rev., 2012, 64(1), 166-187.
[http://dx.doi.org/10.1124/pr.110.003905] [PMID: 22106091 ]
[36]
Cantó, C.; Houtkooper, R.H.; Pirinen, E.; Youn, D.Y.; Oosterveer, M.H.; Cen, Y.; Fernandez-Marcos, P.J.; Yamamoto, H.; Andreux, P.A.; Cettour-Rose, P.; Gademann, K.; Rinsch, C.; Schoonjans, K.; Sauve, A.A.; Auwerx, J. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab., 2012, 15(6), 838-847.
[http://dx.doi.org/10.1016/j.cmet.2012.04.022] [PMID: 22682224 ]
[37]
Yoshino, J.; Mills, K.F.; Yoon, M.J.; Imai, S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab., 2011, 14(4), 528-536.
[http://dx.doi.org/10.1016/j.cmet.2011.08.014] [PMID: 21982712 ]
[38]
Castro-Portuguez, R.; Sutphin, G.L. Kynurenine pathway, NAD+ synthesis, and mitochondrial function: Targeting tryptophan metabolism to promote longevity and healthspan. Exp. Gerontol., 2020, 132, 110841.
[http://dx.doi.org/10.1016/j.exger.2020.110841] [PMID: 31954874 ]
[39]
Phillips, R.S.; Iradukunda, E.C.; Hughes, T.; Bowen, J.P. Modulation of Enzyme Activity in the Kynurenine Pathway by Kynurenine Monooxygenase Inhibition. Front. Mol. Biosci., 2019, 6(3), 3.
[http://dx.doi.org/10.3389/fmolb.2019.00003] [PMID: 30800661 ]
[40]
Yamazaki, F.; Kuroiwa, T.; Takikawa, O.; Kido, R. Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme. Biochem. J., 1985, 230(3), 635-638.
[http://dx.doi.org/10.1042/bj2300635] [PMID: 3877502]
[41]
Yuasa, H.J.; Sugiura, M.; Harumoto, T. A single amino acid residue regulates the substrate affinity and specificity of indoleamine 2,3-dioxygenase. Arch. Biochem. Biophys., 2018, 640, 1-9.
[http://dx.doi.org/10.1016/j.abb.2017.12.019] [PMID: 29288638 ]
[42]
Hu, B.; Hissong, B.D.; Carlin, J.M. Interleukin-1 enhances indoleamine 2,3-dioxygenase activity by increasing specific mRNA expression in human mononuclear phagocytes. J. Interferon Cytokine Res., 1995, 15(7), 617-624.
[http://dx.doi.org/10.1089/jir.1995.15.617] [PMID: 7553232 ]
[43]
Babcock, T.A.; Carlin, J.M. Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells. Cytokine, 2000, 12(6), 588-594.
[http://dx.doi.org/10.1006/cyto.1999.0661] [PMID: 10843733 ]
[44]
Yoshida, R.; Hayaishi, O. Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide. Proc. Natl. Acad. Sci. USA, 1978, 75(8), 3998-4000.
[http://dx.doi.org/10.1073/pnas.75.8.3998] [PMID: 279015]
[45]
Muller, A.J.; DuHadaway, J.B.; Donover, P.S.; Sutanto-Ward, E.; Prendergast, G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med., 2005, 11(3), 312-319.
[http://dx.doi.org/10.1038/nm1196] [PMID: 15711557 ]
[46]
Muller, A.J.; Malachowski, W.P.; Prendergast, G.C. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin. Ther. Targets, 2005, 9(4), 831-849.
[http://dx.doi.org/10.1517/14728222.9.4.831] [PMID: 16083346 ]
[47]
Cady, S.G.; Sono, M. 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch. Biochem. Biophys., 1991, 291(2), 326-333.
[http://dx.doi.org/10.1016/0003-9861(91)90142-6] [PMID: 1952947 ]
[48]
Jackson, E.; Dees, E. C.; Kauh, J. S.; Harvey, R. D.; Neuger, A.; Lush, R.; Antonia, S. J.; Minton, S. E.; Ismail-Khan, R.; Han, H. S.; Vahanian, N. N.; Ramsey, W. J.; Link, C. J.; Streicher, H.; Sullivan, D.; Soliman, H. H. A phase I study of indoximod in combination with docetaxel in metastatic solid tumors. J. Clin. Onco., 2013, 31(15_suppl), 3026-3026.
[http://dx.doi.org/10.1200/jco.2013.31.15_suppl.3026]
[49]
Jha, G. G.; Gupta, S.; Tagawa, S. T.; Koopmeiners, J. S.; Vivek, S.; Dudek, A. Z.; Cooley, S. A.; Blazar, B. R.; Miller, J. S. A phase II randomized, double-blind study of sipuleucel- T followed by IDO pathway inhibitor, indoximod, or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC). J. Clin. Onco., 2017, 35(15_suppl), 3066-3066.
[50]
Zakharia, Y.; Rixe, O.; Ward, J. H.; Drabick, J. J.; Shaheen, M. F.; Milhem, M. M.; Munn, D.; Kennedy, E. P.; Vahanian, N. N.; Link, C. J.; McWilliams, R. R. Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma. J. Clin. Onco., 2018, 36(15_suppl), 9512-9512.
[http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.9512]
[51]
Prendergast, G.C.; Metz, R. A perspective on new immune adjuvant principles: Reprogramming inflammatory states to permit clearance of cancer cells and other age-associated cellular pathologies. OncoImmunology, 2012, 1(6), 924-929.
[http://dx.doi.org/10.4161/onci.21358] [PMID: 23162760 ]
[52]
Yue, E.W.; Sparks, R.; Polam, P.; Modi, D.; Douty, B.; Wayland, B.; Glass, B.; Takvorian, A.; Glenn, J.; Zhu, W.; Bower, M.; Liu, X.; Leffet, L.; Wang, Q.; Bowman, K.J.; Hansbury, M.J.; Wei, M.; Li, Y.; Wynn, R.; Burn, T.C.; Koblish, H.K.; Fridman, J.S.; Emm, T.; Scherle, P.A.; Metcalf, B.; Combs, A.P. INCB24360 (Epacadostat), a highly potent and selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology. ACS Med. Chem. Lett., 2017, 8(5), 486-491.
[http://dx.doi.org/10.1021/acsmedchemlett.6b00391] [PMID: 28523098 ]
[53]
Long, G.V.; Dummer, R.; Hamid, O.; Gajewski, T.F.; Caglevic, C.; Dalle, S.; Arance, A.; Carlino, M.S.; Grob, J.J.; Kim, T.M.; Demidov, L.; Robert, C.; Larkin, J.; Anderson, J.R.; Maleski, J.; Jones, M.; Diede, S.J.; Mitchell, T.C. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol., 2019, 20(8), 1083-1097.
[http://dx.doi.org/10.1016/S1470-2045(19)30274-8] [PMID: 31221619 ]
[54]
Kumar, S.; Jaller, D.; Patel, B.; LaLonde, J.M.; DuHadaway, J.B.; Malachowski, W.P.; Prendergast, G.C.; Muller, A.J. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J. Med. Chem., 2008, 51(16), 4968-4977.
[http://dx.doi.org/10.1021/jm800512z] [PMID: 18665584 ]
[55]
Röhrig, U.F.; Majjigapu, S.R.; Grosdidier, A.; Bron, S.; Stroobant, V.; Pilotte, L.; Colau, D.; Vogel, P.; Van den Eynde, B.J.; Zoete, V.; Michielin, O. Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition. J. Med. Chem., 2012, 55(11), 5270-5290.
[http://dx.doi.org/10.1021/jm300260v] [PMID: 22616902 ]
[56]
Mautino, M.R.; Jaipuri, F.A.; Waldo, J.; Kumar, S.; Adams, J.; Van Allen, C.; Marcinowicz-Flick, A.; Munn, D.; Vahanian, N.; Link, C.J. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. Cancer Res., 2013, 73(8)(Suppl.), 491-491.
[57]
Jung, K.H.; LoRusso, P.; Burris, H.; Gordon, M.; Bang, Y.J.; Hellmann, M.D.; Cervantes, A.; Ochoa de Olza, M.; Marabelle, A.; Hodi, F.S.; Ahn, M.J.; Emens, L.A.; Barlesi, F.; Hamid, O.; Calvo, E.; McDermott, D.; Soliman, H.; Rhee, I.; Lin, R.; Pourmohamad, T.; Suchomel, J.; Tsuhako, A.; Morrissey, K.; Mahrus, S.; Morley, R.; Pirzkall, A.; Davis, S.L.; Phase, I.; Phase, I. Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Clin. Cancer Res., 2019, 25(11), 3220-3228.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-2740] [PMID: 30770348]
[58]
Yamamoto, N.; Fujiwara, Y.; Kondo, S.; Iwasa, S.; Yonemori, K.; Shimomura, A.; Kitano, S.; Shimizu, T.; Koyama, T.; Ebata, T.; Sato, N.; Nakai, K.; Inatani, M.; Tamura, K. Phase I study of IDO1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with atezolizumab in Japanese patients with advanced solid tumors. Ann. Oncol., 2018, 29(Suppl. 8), VIII138-VIII139.
[http://dx.doi.org/10.1093/annonc/mdy279.411 ]
[59]
Zwilling, D.; Huang, S.Y.; Sathyasaikumar, K.V.; Notarangelo, F.M.; Guidetti, P.; Wu, H.Q.; Lee, J.; Truong, J.; Andrews-Zwilling, Y.; Hsieh, E.W.; Louie, J.Y.; Wu, T.; Scearce-Levie, K.; Patrick, C.; Adame, A.; Giorgini, F.; Moussaoui, S.; Laue, G.; Rassoulpour, A.; Flik, G.; Huang, Y.; Muchowski, J.M.; Masliah, E.; Schwarcz, R.; Muchowski, P.J. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell, 2011, 145(6), 863-874.
[http://dx.doi.org/10.1016/j.cell.2011.05.020] [PMID: 21640374 ]
[60]
Perkins, M.N.; Stone, T.W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res., 1982, 247(1), 184-187.
[http://dx.doi.org/10.1016/0006-8993(82)91048-4] [PMID: 6215086 ]
[61]
Hilmas, C.; Pereira, E.F.; Alkondon, M.; Rassoulpour, A.; Schwarcz, R.; Albuquerque, E.X. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J. Neurosci., 2001, 21(19), 7463-7473.
[http://dx.doi.org/10.1523/JNEUROSCI.21-19-07463.2001] [PMID: 11567036 ]
[62]
Okuda, S.; Nishiyama, N.; Saito, H.; Katsuki, H. Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc. Natl. Acad. Sci. USA, 1996, 93(22), 12553-12558.
[http://dx.doi.org/10.1073/pnas.93.22.12553] [PMID: 8901620 ]
[63]
Okuda, S.; Nishiyama, N.; Saito, H.; Katsuki, H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J. Neurochem., 1998, 70(1), 299-307.
[http://dx.doi.org/10.1046/j.1471-4159.1998.70010299.x] [PMID: 9422375 ]
[64]
Mole, D.J.; Webster, S.P.; Uings, I.; Zheng, X.; Binnie, M.; Wilson, K.; Hutchinson, J.P.; Mirguet, O.; Walker, A.; Beaufils, B.; Ancellin, N.; Trottet, L.; Bénéton, V.; Mowat, C.G.; Wilkinson, M.; Rowland, P.; Haslam, C.; McBride, A.; Homer, N.Z.; Baily, J.E.; Sharp, M.G.; Garden, O.J.; Hughes, J.; Howie, S.E.; Holmes, D.S.; Liddle, J.; Iredale, J.P. Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis. Nat. Med., 2016, 22(2), 202-209.
[http://dx.doi.org/10.1038/nm.4020] [PMID: 26752518 ]
[65]
Pellicciari, R.; Natalini, B.; Costantino, G.; Mahmoud, M.R.; Mattoli, L.; Sadeghpour, B.M.; Moroni, F.; Chiarugi, A.; Carpenedo, R. Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase. J. Med. Chem., 1994, 37(5), 647-655.
[http://dx.doi.org/10.1021/jm00031a015] [PMID: 8126705 ]
[66]
Speciale, C.; Wu, H.Q.; Cini, M.; Marconi, M.; Varasi, M.; Schwarcz, R. (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur. J. Pharmacol., 1996, 315(3), 263-267.
[http://dx.doi.org/10.1016/S0014-2999(96)00613-9] [PMID: 8982663 ]
[67]
Pellicciari, R.; Amori, L.; Costantino, G.; Giordani, A.; Macchiarulo, A.; Mattoli, L.; Pevarello, P.; Speciale, C.; Varasi, M. Modulation of the kynurine pathway of tryptophan metabolism in search for neuroprotective agents. Focus on kynurenine-3-hydroxylase. Adv. Exp. Med. Biol., 2003, 527, 621-628.
[http://dx.doi.org/10.1007/978-1-4615-0135-0_71] [PMID: 15206781 ]
[68]
Amaral, M.; Levy, C.; Heyes, D.J.; Lafite, P.; Outeiro, T.F.; Giorgini, F.; Leys, D.; Scrutton, N.S. Structural basis of kynurenine 3-monooxygenase inhibition. Nature, 2013, 496(7445), 382-385.
[http://dx.doi.org/10.1038/nature12039] [PMID: 23575632 ]
[69]
Röver, S.; Cesura, A.M.; Huguenin, P.; Kettler, R.; Szente, A. Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J. Med. Chem., 1997, 40(26), 4378-4385.
[http://dx.doi.org/10.1021/jm970467t] [PMID: 9435907 ]
[70]
Hutchinson, J.P.; Rowland, P.; Taylor, M.R.D.; Christodoulou, E.M.; Haslam, C.; Hobbs, C.I.; Holmes, D.S.; Homes, P.; Liddle, J.; Mole, D.J.; Uings, I.; Walker, A.L.; Webster, S.P.; Mowat, C.G.; Chung, C.W. Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase. Nat. Commun., 2017, 8, 15827.
[http://dx.doi.org/10.1038/ncomms15827] [PMID: 28604669]
[71]
Pevarello, P.; Varasi, M.; Amici, R.; Toma, S.; Speciale, C. Tricyclic 3-oxo-propanenitrile Compounds. WO 1999/ 016753 A2 1999.
[72]
Lowe, D.M.; Gee, M.; Haslam, C.; Leavens, B.; Christodoulou, E.; Hissey, P.; Hardwicke, P.; Argyrou, A.; Webster, S.P.; Mole, D.J.; Wilson, K.; Binnie, M.; Yard, B.A.; Dean, T.; Liddle, J.; Uings, I.; Hutchinson, J.P. Lead discovery for human kynurenine 3-monooxygenase by high-throughput RapidFire mass spectrometry. J. Biomol. Screen., 2014, 19(4), 508-515.
[http://dx.doi.org/10.1177/1087057113518069] [PMID: 24381207 ]
[73]
Toledo-Sherman, L.M.; Prime, M.E.; Mrzljak, L.; Beconi, M.G.; Beresford, A.; Brookfield, F.A.; Brown, C.J.; Cardaun, I.; Courtney, S.M.; Dijkman, U.; Hamelin-Flegg, E.; Johnson, P.D.; Kempf, V.; Lyons, K.; Matthews, K.; Mitchell, W.L.; O’Connell, C.; Pena, P.; Powell, K.; Rassoulpour, A.; Reed, L.; Reindl, W.; Selvaratnam, S.; Friley, W.W.; Weddell, D.A.; Went, N.E.; Wheelan, P.; Winkler, C.; Winkler, D.; Wityak, J.; Yarnold, C.J.; Yates, D.; Munoz-Sanjuan, I.; Dominguez, C. Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington’s disease. J. Med. Chem., 2015, 58(3), 1159-1183.
[http://dx.doi.org/10.1021/jm501350y] [PMID: 25590515 ]
[74]
Beaumont, V.; Mrzljak, L.; Dijkman, U.; Freije, R.; Heins, M.; Rassoulpour, A.; Tombaugh, G.; Gelman, S.; Bradaia, A.; Steidl, E.; Gleyzes, M.; Heikkinen, T.; Lehtimäki, K.; Puoliväli, J.; Kontkanen, O.; Javier, R.M.; Neagoe, I.; Deisemann, H.; Winkler, D.; Ebneth, A.; Khetarpal, V.; Toledo-Sherman, L.; Dominguez, C.; Park, L.C.; Munoz-Sanjuan, I. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington’s disease. Exp. Neurol., 2016, 282, 99-118.
[http://dx.doi.org/10.1016/j.expneurol.2016.05.005] [PMID: 27163548 ]
[75]
Phillips, R.S. Structure and mechanism of kynureninase. Arch. Biochem. Biophys., 2014, 544, 69-74.
[http://dx.doi.org/10.1016/j.abb.2013.10.020] [PMID: 24200862 ]
[76]
Lima, S.; Kumar, S.; Gawandi, V.; Momany, C.; Phillips, R.S. Crystal structure of the Homo sapiens kynureninase-3-hydroxyhippuric acid inhibitor complex: insights into the molecular basis of kynureninase substrate specificity. J. Med. Chem., 2009, 52(2), 389-396.
[http://dx.doi.org/10.1021/jm8010806] [PMID: 19143568 ]
[77]
Phillips, R.S.; Dua, R.K. Stereochemistry and mechanism of aldol reactions catalyzed by kynureninase. J. Am. Chem. Soc., 1991, 113(19), 7385-7388.
[http://dx.doi.org/10.1021/ja00019a039]
[78]
Dua, R.K.; Taylor, E.W.; Phillips, R.S. S-Aryl-L-cysteine S,S-dioxides: design, synthesis, and evaluation of a new class of inhibitors of kynureninase. J. Am. Chem. Soc., 1993, 115(4), 1264-1270.
[http://dx.doi.org/10.1021/ja00057a007]
[79]
Ross, F.C.; Botting, N.P.; Leeson, P.D. Synthesis of phosphinic acid transition state analogues for the reaction catalysed by kynureninase. Bioorg. Med. Chem. Lett., 1996, 6(22), 2643-2646.
[http://dx.doi.org/10.1016/S0960-894X(96)00483-0]
[80]
Walsh, H.A.; Leslie, P.L.; O’Shea, K.C.; Botting, N.P. 2-Amino-4-[3′-hydroxyphenyl]-4-hydroxybutanoic acid; a potent inhibitor of rat and recombinant human kynureninase. Bioorg. Med. Chem. Lett., 2002, 12(3), 361-363.
[http://dx.doi.org/10.1016/S0960-894X(01)00758-2] [PMID: 11814797 ]
[81]
Iwai, K.; Taguchi, H. Distribution of quinolinate phosphoribosyl-transferase in animals, plants and microorganisms. J. Nutr. Sci. Vitaminol. (Tokyo), 1973, 19(6), 491-499.
[http://dx.doi.org/10.3177/jnsv.19.491] [PMID: 4799479 ]
[82]
Buonvicino, D.; Mazzola, F.; Zamporlini, F.; Resta, F.; Ranieri, G.; Camaioni, E.; Muzzi, M.; Zecchi, R.; Pieraccini, G.; Dolle, C.; Calamante, M.; Bartolucci, G.; Ziegler, M.; Stecca, B.; Raffaelli, N.; Chiarugi, A. Identification of the nicotinamide salvage pathway as a new toxification route for antimetabolites. Cell Chem Biol,, 2018, 25(4), 471-482., e7.
[http://dx.doi.org/10.1016/j.chembiol.2018.01.012]
[83]
Sahm, F.; Oezen, I.; Opitz, C.A.; Radlwimmer, B.; von Deimling, A.; Ahrendt, T.; Adams, S.; Bode, H.B.; Guillemin, G.J.; Wick, W.; Platten, M. The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. Cancer Res., 2013, 73(11), 3225-3234.
[http://dx.doi.org/10.1158/0008-5472.CAN-12-3831] [PMID: 23548271 ]
[84]
Malik, S.S.; Patterson, D.N.; Ncube, Z.; Toth, E.A. The crystal structure of human quinolinic acid phosphoribosyltransferase in complex with its inhibitor phthalic acid. Proteins, 2014, 82(3), 405-414.
[http://dx.doi.org/10.1002/prot.24406] [PMID: 24038671 ]
[85]
Braidy, N.; Guillemin, G.J.; Grant, R. Effects of Kynurenine Pathway Inhibition on NAD Metabolism and Cell Viability in Human Primary Astrocytes and Neurons. Int. J. Tryptophan Res., 2011, 4, 29-37.
[http://dx.doi.org/10.4137/IJTR.S7052] [PMID: 22084601 ]
[86]
Berger, F.; Lau, C.; Dahlmann, M.; Ziegler, M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J. Biol. Chem., 2005, 280(43), 36334-36341.
[http://dx.doi.org/10.1074/jbc.M508660200] [PMID: 16118205 ]
[87]
Liu, X.; Liu, M.; Tang, C.; Xiang, Z.; Li, Q.; Ruan, X.; Xiong, K.; Zheng, L. Overexpression of Nmnat improves the adaption of health span in aging Drosophila. Exp. Gerontol., 2018, 108, 276-283.
[http://dx.doi.org/10.1016/j.exger.2018.04.026] [PMID: 29727704 ]
[88]
Gulshan, M.; Yaku, K.; Okabe, K.; Mahmood, A.; Sasaki, T.; Yamamoto, M.; Hikosaka, K.; Usui, I.; Kitamura, T.; Tobe, K.; Nakagawa, T. Overexpression of Nmnat3 efficiently increases NAD and NGD levels and ameliorates age-associated insulin resistance. Aging Cell, 2018, 17(4), e12798.
[http://dx.doi.org/10.1111/acel.12798] [PMID: 29901258 ]
[89]
Anderson, R.M.; Bitterman, K.J.; Wood, J.G.; Medvedik, O.; Cohen, H.; Lin, S.S.; Manchester, J.K.; Gordon, J.I.; Sinclair, D.A. Manipulation of a nuclear NAD+ salvage pathway delays aging without altering steady-state NAD+ levels. J. Biol. Chem., 2002, 277(21), 18881-18890.
[http://dx.doi.org/10.1074/jbc.M111773200] [PMID: 11884393 ]
[90]
Ali, Y.O.; Li-Kroeger, D.; Bellen, H.J.; Zhai, R.G.; Lu, H.C. NMNATs, evolutionarily conserved neuronal maintenance factors. Trends Neurosci., 2013, 36(11), 632-640.
[http://dx.doi.org/10.1016/j.tins.2013.07.002] [PMID: 23968695 ]
[91]
Yahata, N.; Yuasa, S.; Araki, T. Nicotinamide mononucleotide adenylyltransferase expression in mitochondrial matrix delays Wallerian degeneration. J. Neurosci., 2009, 29(19), 6276-6284.
[http://dx.doi.org/10.1523/JNEUROSCI.4304-08.2009] [PMID: 19439605 ]
[92]
Tang, B.L. Why is NMNAT Protective against Neuronal Cell Death and Axon Degeneration, but Inhibitory of Axon Regeneration? Cells, 2019, 8(3), E267.
[http://dx.doi.org/10.3390/cells8030267] [PMID: 30901919 ]
[93]
Cui, C.; Qi, J.; Deng, Q.; Chen, R.; Zhai, D.; Yu, J. Nicotinamide Mononucleotide Adenylyl Transferase 2: A promising diagnostic and therapeutic target for colorectal cancer. BioMed Res. Int., 2016, 2016, 1804137.
[http://dx.doi.org/10.1155/2016/1804137] [PMID: 27218101 ]
[94]
Pan, L.Z.; Ahn, D.G.; Sharif, T.; Clements, D.; Gujar, S.A.; Lee, P.W. The NAD+ synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target. Cell Cycle, 2014, 13(6), 1041-1048.
[http://dx.doi.org/10.4161/cc.28128] [PMID: 24552824 ]
[95]
Li, H.; Feng, Z.; Wu, W.; Li, J.; Zhang, J.; Xia, T. SIRT3 regulates cell proliferation and apoptosis related to energy metabolism in non-small cell lung cancer cells through deacetylation of NMNAT2. Int. J. Oncol., 2013, 43(5), 1420-1430.
[http://dx.doi.org/10.3892/ijo.2013.2103] [PMID: 24042441 ]
[96]
Imai, S. Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr. Pharm. Des., 2009, 15(1), 20-28.
[http://dx.doi.org/10.2174/138161209787185814] [PMID: 19149599 ]
[97]
Samal, B.; Sun, Y.; Stearns, G.; Xie, C.; Suggs, S.; McNiece, I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol., 1994, 14(2), 1431-1437.
[http://dx.doi.org/10.1128/MCB.14.2.1431] [PMID: 8289818 ]
[98]
Fukuhara, A.; Matsuda, M.; Nishizawa, M.; Segawa, K.; Tanaka, M.; Kishimoto, K.; Matsuki, Y.; Murakami, M.; Ichisaka, T.; Murakami, H.; Watanabe, E.; Takagi, T.; Akiyoshi, M.; Ohtsubo, T.; Kihara, S.; Yamashita, S.; Makishima, M.; Funahashi, T.; Yamanaka, S.; Hiramatsu, R.; Matsuzawa, Y.; Shimomura, I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 2005, 307(5708), 426-430.
[http://dx.doi.org/10.1126/science.1097243] [PMID: 15604363]
[99]
Revollo, J.R.; Körner, A.; Mills, K.F.; Satoh, A.; Wang, T.; Garten, A.; Dasgupta, B.; Sasaki, Y.; Wolberger, C.; Townsend, R.R.; Milbrandt, J.; Kiess, W.; Imai, S. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab., 2007, 6(5), 363-375.
[http://dx.doi.org/10.1016/j.cmet.2007.09.003] [PMID: 17983582 ]
[100]
Reddy, P.S.; Umesh, S.; Thota, B.; Tandon, A.; Pandey, P.; Hegde, A.S.; Balasubramaniam, A.; Chandramouli, B.A.; Santosh, V.; Rao, M.R.; Kondaiah, P.; Somasundaram, K. PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol. Ther., 2008, 7(5), 663-668.
[http://dx.doi.org/10.4161/cbt.7.5.5663] [PMID: 18728403 ]
[101]
Maldi, E.; Travelli, C.; Caldarelli, A.; Agazzone, N.; Cintura, S.; Galli, U.; Scatolini, M.; Ostano, P.; Miglino, B.; Chiorino, G.; Boldorini, R.; Genazzani, A.A. Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions. Pigment Cell Melanoma Res., 2013, 26(1), 144-146.
[http://dx.doi.org/10.1111/pcmr.12037] [PMID: 23051650 ]
[102]
Olesen, U.H.; Hastrup, N.; Sehested, M. Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas. APMIS, 2011, 119(4-5), 296-303.
[http://dx.doi.org/10.1111/j.1600-0463.2011.02733.x] [PMID: 21492230 ]
[103]
Galli, U.; Travelli, C.; Massarotti, A.; Fakhfouri, G.; Rahimian, R.; Tron, G.C.; Genazzani, A.A. Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. J. Med. Chem., 2013, 56(16), 6279-6296.
[http://dx.doi.org/10.1021/jm4001049] [PMID: 23679915 ]
[104]
Sampath, D.; Zabka, T.S.; Misner, D.L.; O’Brien, T.; Dragovich, P.S. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer. Pharmacol. Ther., 2015, 151, 16-31.
[http://dx.doi.org/10.1016/j.pharmthera.2015.02.004] [PMID: 25709099]
[105]
Wosikowski, K.; Mattern, K.; Schemainda, I.; Hasmann, M.; Rattel, B.; Löser, R. WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. Cancer Res., 2002, 62(4), 1057-1062.
[PMID: 11861382]
[106]
Hasmann, M.; Schemainda, I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res., 2003, 63(21), 7436-7442.
[PMID: 14612543 ]
[107]
Goldinger, S.M.; Gobbi Bischof, S.; Fink-Puches, R.; Klemke, C.D.; Dréno, B.; Bagot, M.; Dummer, R. Efficacy and Safety of APO866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma: A Phase 2 Clinical Trial. JAMA Dermatol., 2016, 152(7), 837-839.
[http://dx.doi.org/10.1001/jamadermatol.2016.0401] [PMID: 27007550 ]
[108]
Olesen, U.H.; Christensen, M.K.; Björkling, F.; Jäättelä, M.; Jensen, P.B.; Sehested, M.; Nielsen, S.J. Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem. Biophys. Res. Commun., 2008, 367(4), 799-804.
[http://dx.doi.org/10.1016/j.bbrc.2008.01.019] [PMID: 18201551 ]
[109]
Watson, M.; Roulston, A.; Bélec, L.; Billot, X.; Marcellus, R.; Bédard, D.; Bernier, C.; Branchaud, S.; Chan, H.; Dairi, K.; Gilbert, K.; Goulet, D.; Gratton, M.O.; Isakau, H.; Jang, A.; Khadir, A.; Koch, E.; Lavoie, M.; Lawless, M.; Nguyen, M.; Paquette, D.; Turcotte, E.; Berger, A.; Mitchell, M.; Shore, G.C.; Beauparlant, P. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol. Cell. Biol., 2009, 29(21), 5872-5888.
[http://dx.doi.org/10.1128/MCB.00112-09] [PMID: 19703994 ]
[110]
Beauparlant, P.; Bédard, D.; Bernier, C.; Chan, H.; Gilbert, K.; Goulet, D.; Gratton, M.O.; Lavoie, M.; Roulston, A.; Turcotte, E.; Watson, M. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anticancer Drugs, 2009, 20(5), 346-354.
[http://dx.doi.org/10.1097/CAD.0b013e3283287c20] [PMID: 19369827 ]
[111]
You, H.; Youn, H.S. Im, I.; Bae, M.H.; Lee, S.K.; Ko, H.; Eom, S.H.; Kim, Y.C. Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents. Eur. J. Med. Chem., 2011, 46(4), 1153-1164.
[http://dx.doi.org/10.1016/j.ejmech.2011.01.034] [PMID: 21330015 ]
[112]
Gunzner-Toste, J.; Zhao, G.; Bauer, P.; Baumeister, T.; Buckmelter, A.J.; Caligiuri, M.; Clodfelter, K.H.; Fu, B.; Han, B.; Ho, Y.C.; Kley, N.; Liang, X.; Liederer, B.M.; Lin, J.; Mukadam, S.; O’Brien, T.; Oh, A.; Reynolds, D.J.; Sharma, G.; Skelton, N.; Smith, C.C.; Sodhi, J.; Wang, W.; Wang, Z.; Xiao, Y.; Yuen, P.W.; Zak, M.; Zhang, L.; Zheng, X.; Bair, K.W.; Dragovich, P.S. Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties. Bioorg. Med. Chem. Lett., 2013, 23(12), 3531-3538.
[http://dx.doi.org/10.1016/j.bmcl.2013.04.040] [PMID: 23668988 ]
[113]
Zheng, X.; Bauer, P.; Baumeister, T.; Buckmelter, A.J.; Caligiuri, M.; Clodfelter, K.H.; Han, B.; Ho, Y.C.; Kley, N.; Lin, J.; Reynolds, D.J.; Sharma, G.; Smith, C.C.; Wang, Z.; Dragovich, P.S.; Oh, A.; Wang, W.; Zak, M.; Gunzner-Toste, J.; Zhao, G.; Yuen, P.W.; Bair, K.W. Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors. J. Med. Chem., 2013, 56(12), 4921-4937.
[http://dx.doi.org/10.1021/jm400186h] [PMID: 23617784 ]
[114]
Colombano, G.; Travelli, C.; Galli, U.; Caldarelli, A.; Chini, M.G.; Canonico, P.L.; Sorba, G.; Bifulco, G.; Tron, G.C.; Genazzani, A.A. A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry. J. Med. Chem., 2010, 53(2), 616-623.
[http://dx.doi.org/10.1021/jm9010669] [PMID: 19961183 ]
[115]
Xu, T.Y.; Zhang, S.L.; Dong, G.Q.; Liu, X.Z.; Wang, X.; Lv, X.Q.; Qian, Q.J.; Zhang, R.Y.; Sheng, C.Q.; Miao, C.Y. Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase. Sci. Rep., 2015, 5, 10043.
[http://dx.doi.org/10.1038/srep10043] [PMID: 26040985 ]
[116]
Estoppey, D.; Hewett, J.W.; Guy, C.T.; Harrington, E.; Thomas, J.R.; Schirle, M.; Cuttat, R.; Waldt, A.; Gerrits, B.; Yang, Z.; Schuierer, S.; Pan, X.; Xie, K.; Carbone, W.; Knehr, J.; Lindeman, A.; Russ, C.; Frias, E.; Hoffman, G.R.; Varadarajan, M.; Ramadan, N.; Reece-Hoyes, J.S.; Wang, Q.; Chen, X.; McAllister, G.; Roma, G.; Bouwmeester, T.; Hoepfner, D. Identification of a novel NAMPT inhibitor by CRISPR/Cas9 chemogenomic profiling in mammalian cells. Sci. Rep., 2017, 7, 42728.
[http://dx.doi.org/10.1038/srep42728] [PMID: 28205648 ]
[117]
Fleischer, T.C.; Murphy, B.R.; Flick, J.S.; Terry-Lorenzo, R.T.; Gao, Z.H.; Davis, T.; McKinnon, R.; Ostanin, K.; Willardsen, J.A.; Boniface, J.J. Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound. Chem. Biol., 2010, 17(6), 659-664.
[http://dx.doi.org/10.1016/j.chembiol.2010.05.008] [PMID: 20609415 ]
[118]
Oh, A.; Ho, Y.C.; Zak, M.; Liu, Y.; Chen, X.; Yuen, P.W.; Zheng, X.; Liu, Y.; Dragovich, P.S.; Wang, W. Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase. ChemBioChem, 2014, 15(8), 1121-1130.
[http://dx.doi.org/10.1002/cbic.201402023] [PMID: 24797455 ]
[119]
Lee, M.W., Jr; Sevryugina, Y.V.; Khan, A.; Ye, S.Q. Carboranes increase the potency of small molecule inhibitors of nicotinamide phosphoribosyltranferase. J. Med. Chem., 2012, 55(16), 7290-7294.
[http://dx.doi.org/10.1021/jm300740t] [PMID: 22889195 ]
[120]
Korepanova, A.; Longenecker, K.L.; Pratt, S.D.; Panchal, S.C.; Clark, R.F.; Lake, M.; Gopalakrishnan, S.M.; Raich, D.; Sun, C.; Petros, A.M. Fragment-based discovery of a potent NAMPT inhibitor. Bioorg. Med. Chem. Lett., 2018, 28(3), 437-440.
[http://dx.doi.org/10.1016/j.bmcl.2017.12.023] [PMID: 29287958 ]
[121]
Korotchkina, L.; Kazyulkin, D.; Komarov, P.G.; Polinsky, A.; Andrianova, E.L.; Joshi, S.; Gupta, M.; Vujcic, S.; Kononov, E.; Toshkov, I.; Tian, Y.; Krasnov, P.; Chernov, M.V.; Veith, J.; Antoch, M.P.; Middlemiss, S.; Somers, K.; Lock, R.B.; Norris, M.D.; Henderson, M.J.; Haber, M.; Chernova, O.B.; Gudkov, A.V. OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. Leukemia, 2020, 34(7), 1828-1839.
[http://dx.doi.org/10.1038/s41375-019-0692-5] [PMID: 31896781 ]
[122]
Talevi, A. Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective. Front. Pharmacol., 2015, 6, 205.
[http://dx.doi.org/10.3389/fphar.2015.00205] [PMID: 26441661 ]
[123]
Zimmermann, G.R.; Lehár, J.; Keith, C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today, 2007, 12(1-2), 34-42.
[http://dx.doi.org/10.1016/j.drudis.2006.11.008] [PMID: 17198971 ]
[124]
Abu Aboud, O.; Chen, C.H.; Senapedis, W.; Baloglu, E.; Argueta, C.; Weiss, R.H. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth. Mol. Cancer Ther., 2016, 15(9), 2119-2129.
[http://dx.doi.org/10.1158/1535-7163.MCT-16-0197] [PMID: 27390344 ]
[125]
Kraus, D.; Reckenbeil, J.; Veit, N.; Kuerpig, S.; Meisenheimer, M.; Beier, I.; Stark, H.; Winter, J.; Probstmeier, R. Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation. Cell Oncol. (Dordr.), 2018, 41(5), 485-494.
[http://dx.doi.org/10.1007/s13402-018-0385-5] [PMID: 29949049 ]
[126]
Dong, G.; Chen, W.; Wang, X.; Yang, X.; Xu, T.; Wang, P.; Zhang, W.; Rao, Y.; Miao, C.; Sheng, C. Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. J. Med. Chem., 2017, 60(19), 7965-7983.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00467] [PMID: 28885834 ]
[127]
Chen, W.; Dong, G.; Wu, Y.; Zhang, W.; Miao, C.; Sheng, C. Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery. ACS Med. Chem. Lett., 2017, 9(1), 34-38.
[http://dx.doi.org/10.1021/acsmedchemlett.7b00414] [PMID: 29348808 ]
[128]
Pieper, A.A.; Xie, S.; Capota, E.; Estill, S.J.; Zhong, J.; Long, J.M.; Becker, G.L.; Huntington, P.; Goldman, S.E.; Shen, C-H.; Capota, M.; Britt, J.K.; Kotti, T.; Ure, K.; Brat, D.J.; Williams, N.S.; MacMillan, K.S.; Naidoo, J.; Melito, L.; Hsieh, J.; De Brabander, J.; Ready, J.M.; McKnight, S.L. Discovery of a proneurogenic, neuroprotective chemical. Cell, 2010, 142(1), 39-51.
[http://dx.doi.org/10.1016/j.cell.2010.06.018] [PMID: 20603013 ]
[129]
Wang, G.; Han, T.; Nijhawan, D.; Theodoropoulos, P.; Naidoo, J.; Yadavalli, S.; Mirzaei, H.; Pieper, A.A.; Ready, J.M.; McKnight, S.L. P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell, 2014, 158(6), 1324-1334.
[http://dx.doi.org/10.1016/j.cell.2014.07.040] [PMID: 25215490 ]
[130]
Gardell, S.J.; Hopf, M.; Khan, A.; Dispagna, M.; Hampton Sessions, E.; Falter, R.; Kapoor, N.; Brooks, J.; Culver, J.; Petucci, C.; Ma, C-T.; Cohen, S.E.; Tanaka, J.; Burgos, E.S.; Hirschi, J.S.; Smith, S.R.; Sergienko, E.; Pinkerton, A.B.; Boosting, N.A.D. Boosting NAD+ with a small molecule that activates NAMPT. Nat. Commun., 2019, 10(1), 3241.
[http://dx.doi.org/10.1038/s41467-019-11078-z] [PMID: 31324777 ]
[131]
Duarte-Pereira, S.; Pereira-Castro, I.; Silva, S.S.; Correia, M.G.; Neto, C.; da Costa, L.T.; Amorim, A.; Silva, R.M. Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors. Oncotarget, 2016, 7(2), 1973-1983.
[http://dx.doi.org/10.18632/oncotarget.6538] [PMID: 26675378 ]
[132]
Piacente, F.; Caffa, I.; Ravera, S.; Sociali, G.; Passalacqua, M.; Vellone, V.G.; Becherini, P.; Reverberi, D.; Monacelli, F.; Ballestrero, A.; Odetti, P.; Cagnetta, A.; Cea, M.; Nahimana, A.; Duchosal, M.; Bruzzone, S.; Nencioni, A. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair. Cancer Res., 2017, 77(14), 3857-3869.
[http://dx.doi.org/10.1158/0008-5472.CAN-16-3079] [PMID: 28507103 ]
[133]
Li, X.Q.; Lei, J.; Mao, L.H.; Wang, Q.L.; Xu, F.; Ran, T.; Zhou, Z.H.; He, S. NAMPT and NAPRT, Key Enzymes in NAD Salvage Synthesis Pathway, Are of Negative Prognostic Value in Colorectal Cancer. Front. Oncol., 2019, 9, 736.
[http://dx.doi.org/10.3389/fonc.2019.00736] [PMID: 31448236 ]
[134]
Marletta, A.S.; Massarotti, A.; Orsomando, G.; Magni, G.; Rizzi, M.; Garavaglia, S. Crystal structure of human nicotinic acid phosphoribosyltransferase. FEBS Open Bio, 2015, 5, 419-428.
[http://dx.doi.org/10.1016/j.fob.2015.05.002] [PMID: 26042198]
[135]
Khan, J.A.; Tao, X.; Tong, L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat. Struct. Mol. Biol., 2006, 13(7), 582-588.
[http://dx.doi.org/10.1038/nsmb1105] [PMID: 16783377 ]
[136]
Gaut, Z.N.; Solomon, H.M. Inhibition of nicotinate phosphoribosyltransferase in human platelet lysate by nicotinic acid analogs. Biochem. Pharmacol., 1971, 20(10), 2903-2906.
[http://dx.doi.org/10.1016/0006-2952(71)90202-4] [PMID: 4255930 ]
[137]
Gaut, Z.N.; Solomon, H.M. Inhibition of nicotinate phosphoribosyl transferase by nonsteroidal anti-inflammatory drugs: a possible mechanism of action. J. Pharm. Sci., 1971, 60(12), 1887-1888.
[http://dx.doi.org/10.1002/jps.2600601230] [PMID: 4333776 ]
[138]
Johnson, S.; Imai, S.I. NAD + biosynthesis, aging, and disease. F1000 Res., 2018, 7, 132.
[http://dx.doi.org/10.12688/f1000research.12120.1] [PMID: 29744033 ]
[139]
Yang, Y.; Sauve, A.A. NAD(+) metabolism: Bioenergetics, signaling and manipulation for therapy. Biochim. Biophys. Acta, 2016, 1864(12), 1787-1800.
[http://dx.doi.org/10.1016/j.bbapap.2016.06.014] [PMID: 27374990 ]
[140]
Yaku, K.; Okabe, K.; Nakagawa, T. NAD metabolism: Implications in aging and longevity. Ageing Res. Rev., 2018, 47, 1-17.
[http://dx.doi.org/10.1016/j.arr.2018.05.006] [PMID: 29883761 ]
[141]
Imai, S.I. The NAD World 2.0: the importance of the inter-tissue communication mediated by NAMPT/NAD+/SIRT1 in mammalian aging and longevity control. NPJ Syst. Biol. Appl., 2016, 2, 16018.
[http://dx.doi.org/10.1038/npjsba.2016.18] [PMID: 28725474 ]
[142]
Qian, S.; Zhang, M.; Chen, Q.L.; He, Y.Y.; Wang, W.; Wang, Z.Y. IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery. RSC Advances, 2016, 6(9), 7575-7581.
[http://dx.doi.org/10.1039/C5RA25046C]
[143]
Houtkooper, R.H.; Cantó, C.; Wanders, R.J.; Auwerx, J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr. Rev., 2010, 31(2), 194-223.
[http://dx.doi.org/10.1210/er.2009-0026] [PMID: 20007326 ]
[144]
Hong, W.; Mo, F.; Zhang, Z.; Huang, M.; Wei, X. Nicotinamide Mononucleotide: A Promising Molecule for Therapy of Diverse Diseases by Targeting NAD+ Metabolism. Front. Cell Dev. Biol., 2020, 8, 246.
[http://dx.doi.org/10.3389/fcell.2020.00246] [PMID: 32411700 ]
[145]
Bertoldo, M. J.; Listijono, D. R.; Ho, W. J.; Riepsamen, A. H.; Goss, D. M.; Richani, D.; Jin, X. L.; Mahbub, S.; Campbell, J. M.; Habibalahi, A.; Loh, W. N.; Youngson, N. A.; Maniam, J.; Wong, A. S. A.; Selesniemi, K.; Bustamante, S.; Li, C.; Zhao, Y.; Marinova, M. B.; Kim, L. J.; Lau, L.; Wu, R. M.; Mikolaizak, A. S.; Araki, T.; Le Couteur, D. G.; Turner, N.; Morris, M. J.; Walters, K. A.; Goldys, E.; O'Neill, C.; Gilchrist, R. B.; Sinclair, D. A.; Homer, H. A.; Wu, L. E. NAD(+) Repletion Rescues Female Fertility during Reproductive Aging. Cell Rep, 2020, 30(6), 1670-1681., e7.
[146]
Billington, R.A.; Travelli, C.; Ercolano, E.; Galli, U.; Roman, C.B.; Grolla, A.A.; Canonico, P.L.; Condorelli, F.; Genazzani, A.A. Characterization of NAD uptake in mammalian cells. J. Biol. Chem., 2008, 283(10), 6367-6374.
[http://dx.doi.org/10.1074/jbc.M706204200] [PMID: 18180302 ]
[147]
Zhang, S.L.; Xu, T.Y.; Yang, Z.L.; Han, S.; Zhao, Q.; Miao, C.Y. Crystal structure-based comparison of two NAMPT inhibitors. Acta Pharmacol. Sin., 2018, 39(2), 294-301.
[http://dx.doi.org/10.1038/aps.2017.80] [PMID: 28858298 ]
[148]
Skelton, L.A.; Ormerod, M.G.; Titley, J.C.; Jackman, A.L. Cell cycle effects of CB30865, a lipophilic quinazoline-based analogue of the antifolate thymidylate synthase inhibitor ICI 198583 with an undefined mechanism of action. Cytometry, 1998, 33(1), 56-66.
[http://dx.doi.org/10.1002/(SICI)1097-0320(19980901)33:1<56:AID-CYTO7>3.0.CO;2-9] [PMID: 9725559 ]
[149]
Dragovich, P.S.; Zhao, G.; Baumeister, T.; Bravo, B.; Giannetti, A.M.; Ho, Y.C.; Hua, R.; Li, G.; Liang, X.; Ma, X.; O’Brien, T.; Oh, A.; Skelton, N.J.; Wang, C.; Wang, W.; Wang, Y.; Xiao, Y.; Yuen, P.W.; Zak, M.; Zhao, Q.; Zheng, X. Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). Bioorg. Med. Chem. Lett., 2014, 24(3), 954-962.
[http://dx.doi.org/10.1016/j.bmcl.2013.12.062] [PMID: 24433859]

Rights & Permissions Print Cite
Article Metrics
75
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy